{"id":53058,"date":"2023-01-18T20:02:19","date_gmt":"2023-01-18T19:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/"},"modified":"2023-01-18T20:02:19","modified_gmt":"2023-01-18T19:02:19","slug":"revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/","title":{"rendered":"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial"},"content":{"rendered":"
\n

\nThis Study Will Help Assess the Time Necessary for Tetranite<\/i>\u00ae<\/i> to Regenerate Bone in the Oral Environment<\/i>\n<\/p>\n

<\/a>
<\/a><\/p>\n

LOWELL, Mass.–(BUSINESS WIRE)–#Biomaterials<\/a>–RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University \u201cG.D’Annunzio\u201d of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite\u00ae, the company\u2019s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.\n<\/p>\n

\nThis study will be conducted at the Center for Advanced Studies and Technology (\u201cCAST\u201d) of the University \u201cG.d\u2019Annunzio\u201d Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor\/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D\u2019Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted.\n<\/p>\n

\n\u201cWe are very pleased to see this study come together after much planning during the COVID-19 pandemic,\u201d said Dr. Sinjari. \u201cWe have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.\u201d\n<\/p>\n

\nCurrently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval.\n<\/p>\n

\nDr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. \u201cThe design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,\u201d said Dr. Fugazzotto. \u201cI believe this technology will be transformative in the way we place dental implants.\u201d\n<\/p>\n

\nAbout RevBio, Inc.<\/b>\n<\/p>\n

\nRevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite\u00ae. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio’s Tetranite technology is not yet approved for commercial use.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMichael Tiedemann
\n
mtiedemann@revbio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

This Study Will Help Assess the Time Necessary for Tetranite\u00ae to Regenerate Bone in the Oral Environment LOWELL, Mass.–(BUSINESS WIRE)–#Biomaterials–RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University \u201cG.D’Annunzio\u201d of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53058","6":"format-standard","7":"category-industry"},"yoast_head":"\nRevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"This Study Will Help Assess the Time Necessary for Tetranite\u00ae to Regenerate Bone in the Oral Environment LOWELL, Mass.–(BUSINESS WIRE)–#Biomaterials–RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University \u201cG.D’Annunzio\u201d of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T19:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230117006135\/en\/1688556\/21\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial\",\"datePublished\":\"2023-01-18T19:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/\"},\"wordCount\":451,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117006135\\\/en\\\/1688556\\\/21\\\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/\",\"name\":\"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117006135\\\/en\\\/1688556\\\/21\\\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg\",\"datePublished\":\"2023-01-18T19:02:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117006135\\\/en\\\/1688556\\\/21\\\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230117006135\\\/en\\\/1688556\\\/21\\\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/","og_locale":"en_US","og_type":"article","og_title":"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial - Pharma Trend","og_description":"This Study Will Help Assess the Time Necessary for Tetranite\u00ae to Regenerate Bone in the Oral Environment LOWELL, Mass.–(BUSINESS WIRE)–#Biomaterials–RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University \u201cG.D’Annunzio\u201d of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-18T19:02:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230117006135\/en\/1688556\/21\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial","datePublished":"2023-01-18T19:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/"},"wordCount":451,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230117006135\/en\/1688556\/21\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/","url":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/","name":"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230117006135\/en\/1688556\/21\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg","datePublished":"2023-01-18T19:02:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230117006135\/en\/1688556\/21\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230117006135\/en\/1688556\/21\/NEWLY_DEPOSITED_BONE_W_OSTEOBLAST_W_LOGO_TM.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/revbio-receives-approval-to-start-a-dental-clinical-trial-in-italy-for-its-regenerative-biomaterial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53058"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53058\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}